Nexentis Technologies Inc. Insider Trading

NXTS

⊜ Compare

Last 12 months

No open-market buying or selling by insiders.

The last open-market buy by an executive or director was in Dec 2024.

Net open-market

0 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

0 / 0

executives and directors

Last open-market buy

Dec 2024

Dec 23, 2024

Get an email when NXTS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jan 29	Eun Young Lee Large holder	SoldNo plan	127	$1.36	$173	<0.1%	Form 4
Dec 23, 2024	Ronen Rosenbloom Director	Bought	50,000	—	—	345%	Form 4

Jan 29No plan
Eun Young Lee
Large holder · sold 127 at $1.36
$173
<0.1% of stake
Dec 23, 2024
Ronen Rosenbloom
Director · bought 50,000
—
345% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NXTS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with NXTS

CompareIntrinsic value

LIXTLixte Biotechnology Holdings Inc.

$3.56+0.56%10

CLNNClene Inc.

$3.83-1.79%0

LEXXLexaria Bioscience Corp.

$3.49-7.43%10

BIXTBioxytran Inc.

$0.02+13.28%25

RGBPRegen Biopharma Inc.

$0.00+0.00%25

PLPLPlandai Biotechnology Inc.

$0.00+0.00%30

CYDYCytoDyn Inc.

$0.22-4.35%0

SERSerina Therapeutics Inc.

$1.94+2.65%40

Spot a number that looks wrong? Check it in NXTS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NXTS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.